These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 19843057)

  • 1. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
    Krishna R; Garg A; Panebianco D; Cote J; Bergman AJ; Van Hoydonck P; Laethem T; Van Dyck K; Chen J; Chavez-Eng C; Archer L; Lutz R; Hilliard D; Snyder K; Jin B; Van Bortel L; Lasseter KC; Al-Huniti N; Dykstra K; Gottesdiener K; Wagner JA
    Br J Clin Pharmacol; 2009 Oct; 68(4):535-45. PubMed ID: 19843057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.
    Krishna R; Anderson MS; Bergman AJ; Jin B; Fallon M; Cote J; Rosko K; Chavez-Eng C; Lutz R; Bloomfield DM; Gutierrez M; Doherty J; Bieberdorf F; Chodakewitz J; Gottesdiener KM; Wagner JA
    Lancet; 2007 Dec; 370(9603):1907-14. PubMed ID: 18068514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
    Krishna R; Stypinski D; Ali M; Garg A; Cote J; Maes A; Degroot B; Liu Y; Li S; Connolly SM; Wagner JA; Stoch SA
    Br J Clin Pharmacol; 2012 Jul; 74(1):116-24. PubMed ID: 22243494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
    Krishna R; Garg A; Jin B; Keshavarz SS; Bieberdorf FA; Chodakewitz J; Wagner JA
    Br J Clin Pharmacol; 2009 May; 67(5):520-6. PubMed ID: 19552746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and Pharmacodynamics of Anacetrapib Following Single Doses in Healthy, Young Japanese and White Male Subjects.
    Krishna R; Gheyas F; Liu Y; Cote J; Laterza O; Ruckle JL; Wagner JA; Denker AE
    J Clin Pharmacol; 2018 Feb; 58(2):254-262. PubMed ID: 28884824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
    Krishna R; Bergman AJ; Jin B; Fallon M; Cote J; Van Hoydonck P; Laethem T; Gendrano IN; Van Dyck K; Hilliard D; Laterza O; Snyder K; Chavez-Eng C; Lutz R; Chen J; Bloomfield DM; De Smet M; Van Bortel LM; Gutierrez M; Al-Huniti N; Dykstra K; Gottesdiener KM; Wagner JA
    Clin Pharmacol Ther; 2008 Dec; 84(6):679-83. PubMed ID: 18580870
    [No Abstract]   [Full Text] [Related]  

  • 7. Anacetrapib for the treatment of dyslipidaemia: the last bastion of the cholesteryl ester transfer protein inhibitors?
    Page MM; Hooper AJ; Burnett JR
    Expert Opin Pharmacother; 2016; 17(2):275-81. PubMed ID: 26642232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
    Ford J; Lawson M; Fowler D; Maruyama N; Mito S; Tomiyasu K; Kinoshita S; Suzuki C; Kawaguchi A; Round P; Boyce M; Warrington S; Weber W; van Deventer S; Kastelein JJ
    Br J Clin Pharmacol; 2014 Sep; 78(3):498-508. PubMed ID: 24628035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, Safety and Tolerability of Anacetrapib, a Novel Cholesteryl Ester Transfer Protein (CETP) Inhibitor, After Single and Multiple Doses in Healthy Chinese Subjects.
    Chen H; Chen W; Li H; Xu H; Yuan F; Sheng L; Liu C; Lin P; Yang M; Li X; Liu Y; Walker BM; Gheyas F; Iwamoto M; Stoch SA; Krishna R
    Adv Ther; 2021 Jul; 38(7):3973-3985. PubMed ID: 34101144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholesteryl ester transfer-protein modulator and inhibitors and their potential for the treatment of cardiovascular diseases.
    Shinkai H
    Vasc Health Risk Manag; 2012; 8():323-31. PubMed ID: 22661899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single therapeutic and supratherapeutic doses of anacetrapib, a cholesteryl ester transfer protein inhibitor, do not prolong the QTcF interval in healthy volunteers.
    Lauring B; Liu Y; Li XS; Larson P; Moreau A; Farmer HF; Johnson-Levonas AO; Wagner JA; Lai E
    J Clin Pharmacol; 2014 Jul; 54(7):765-75. PubMed ID: 24615657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of drug distribution into adipose on tissue function: The cholesteryl ester transfer protein (CETP) inhibitor anacetrapib as a test case.
    Johns DG; Wang SP; Rosa R; Hubert J; Xu S; Chen Y; Bateman T; Blaustein RO
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00543. PubMed ID: 31832204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein.
    Boettcher MF; Heinig R; Schmeck C; Kohlsdorfer C; Ludwig M; Schaefer A; Gelfert-Peukert S; Wensing G; Weber O
    Br J Clin Pharmacol; 2012 Feb; 73(2):210-8. PubMed ID: 21838789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in LDL particle concentrations after treatment with the cholesteryl ester transfer protein inhibitor anacetrapib alone or in combination with atorvastatin.
    Krauss RM; Pinto CA; Liu Y; Johnson-Levonas AO; Dansky HM
    J Clin Lipidol; 2015; 9(1):93-102. PubMed ID: 25670366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
    Simic B; Mocharla P; Crucet M; Osto E; Kratzer A; Stivala S; Kühnast S; Speer T; Doycheva P; Princen HM; van der Hoorn JW; Jukema JW; Giral H; Tailleux A; Landmesser U; Staels B; Lüscher TF
    Atherosclerosis; 2017 Feb; 257():186-194. PubMed ID: 28152406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anacetrapib, a cholesterol ester transfer protein (CETP) inhibitor for the treatment of atherosclerosis.
    Masson D
    Curr Opin Investig Drugs; 2009 Sep; 10(9):980-7. PubMed ID: 19705341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anacetrapib, a cholesteryl ester transfer protein inhibitor.
    Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2012 Jan; 21(1):103-9. PubMed ID: 22191425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects.
    Kim CO; Oh ES; Choi C; Kim Y; Lee S; Kim S; Park MS
    Drug Des Devel Ther; 2016; 10():3763-3770. PubMed ID: 27895466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the CYP3A-mediated drug interaction potential of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy volunteers.
    Krishna R; Bergman AJ; Jin B; Garg A; Roadcap B; Chiou R; Dru J; Cote J; Laethem T; Wang RW; Didolkar V; Vets E; Gottesdiener K; Wagner JA
    J Clin Pharmacol; 2009 Jan; 49(1):80-7. PubMed ID: 19004846
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease.
    Gotto AM; Cannon CP; Li XS; Vaidya S; Kher U; Brinton EA; Davidson M; Moon JE; Shah S; Dansky HM; Mitchel Y; Barter P;
    Am J Cardiol; 2014 Jan; 113(1):76-83. PubMed ID: 24188894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.